



## Health Care Inspectorate - Pharmaceutical Affairs and Medical Technology

CERTIFICATE NUMBER: NL/H 16/1013264

### CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>1, 2</sup>

#### Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

Art. 15 of Directive 2001/20/EC

The competent authority of Netherlands confirms the following:

The manufacturer: **Proxy Laboratories, locatie MicroSafe**

Site address: **Darwinweg 24, Leiden, 2333CR, Netherlands**

Has been inspected under the national inspection programme in accordance with Art. 40 of Directive 2001/83/EC and Art. 13 of Directive 2001/20/EC transposed in the following national legislation:

**Art. 100 of the Medicines Act**

**Art. 100 of the Medicines Act**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-12-07**, it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>3</sup> These requirements fulfil the GMP recommendations of WHO.



## Part 2

Human Medicinal Products

Human Investigational Medicinal Products

### 1 MANUFACTURING OPERATIONS

<b>1.1</b>	<b>Sterile products</b>
	<i>1.1.1 Aseptically prepared (processing operations for the following dosage forms)</i> 1.1.1.4 Small volume liquids
	<i>1.1.3 Batch certification</i>
<b>1.3</b>	<b>Biological medicinal products (list of product types)</b>
	<i>1.3.1 Biological medicinal products (list of product types)</i> 1.3.1.5 Biotechnology products
	<i>1.3.2 Batch Certification (list of product types)</i> 1.3.2.5 Biotechnology products
<b>1.5</b>	<b>Packaging</b>
	<i>1.5.2 Secondary packing</i>
<b>1.6</b>	<b>Quality control testing</b>
	<i>1.6.1 Microbiological: sterility</i> <i>1.6.2 Microbiological: non-sterility</i> <i>1.6.4 Biological</i>

Any restrictions related to the scope of this certificate :

**Manufacturing authorisation: 4577 F**

Clarifying remarks (for public users)

**Manufacturing authorisation: 4577 F**



2017-01-15



Name and signature of the authorised person of the  
Competent Authority of Netherlands

*Ing. Mos van Berlo*  
*Health Care Inspectorate - Pharmaceutical Affairs and*  
*Medical Technology*  
Tel: +31 88 1205000  
Fax: +31 88 1205001